-

BiomX Presenting at Three Upcoming Investor Conferences

2022 Aegis Virtual Conference on February 24, 2022

Chardan 4th Annual Microbiome Medicines Summit on March 1, 2022

Oppenheimer & Co. 32nd Annual Virtual Healthcare Conference on March 17, 2022

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer of BiomX, will present at the 2022 Aegis Virtual Conference on February 24, 2022, the Chardan 4th Annual Microbiome Medicines Summit on March 1, 2022 and the Oppenheimer & Co. 32nd Annual Healthcare Conference on March 17, 2022.

2022 Aegis Virtual Conference – February 23-25, 2022

 

 

Date & Time:

Thursday, March 24, 2:30 PM EST

Presenter:

Jonathan Solomon

Conference registration:

Link

 

Chardan 4th Annual Microbiome Medicines Summit – March 1, 2022

 

 

Date & Time:

Tuesday, March 1, 8:30 AM EST

Presenter:

Conference registration:

Jonathon Solomon

Link

 

Oppenheimer & Co. 32nd Annual Healthcare Conference – March 15-17, 2022

 

 

Date & Time:

Thursday, March 17, 2:00 PM EST

Presenter:

Jonathan Solomon

Conference registration:

Link

Live webcasts of presentations will also be accessible through the Investors section of the Company’s website at https://ir.biomx.com/news-events/ir-calendar. Following the events, the webcasts will be archived on the BiomX website.

About BiomX Inc.

BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as target bacteria in the treatment of chronic diseases, such as cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis and colorectal cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. For more information, please visit www.BiomX.com

Contacts

BiomX Contacts

Investor Relations:
LifeSci Advisors, LLC
John Mullaly
(617)-698-9253
jmullaly@lifesciadvisors.com

BiomX, Inc.
Anat Primovich
Corporate Project Manager
+972 (50) 697-7228
anatp@biomx.com

BiomX Inc.

NYSEAM:PHGE

Release Summary
BiomX Presenting at Three Upcoming Investor Conferences
Release Versions

Contacts

BiomX Contacts

Investor Relations:
LifeSci Advisors, LLC
John Mullaly
(617)-698-9253
jmullaly@lifesciadvisors.com

BiomX, Inc.
Anat Primovich
Corporate Project Manager
+972 (50) 697-7228
anatp@biomx.com

More News From BiomX Inc.

BiomX To Present at H.C. Wainwright 24th Annual Global Investment Conference

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer of BiomX, will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022.   H.C Wainwright Global Investment Conference – September 12-14, 2022     Date & Time: Mond...

BiomX Reports Second Quarter 2022 Financial Results and Provides Business Update

BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results, and provided a business update for the second quarter ended June 30, 2022. “It has been an eventful quarter for the Company. We enrolled our first patients in our BX004 cystic fibrosis program, expanded our partnerin...

BiomX to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 10, 2022

BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Wednesday, August 10, 2022, at 8:00 a.m. EDT, to report second quarter 2022 financial results and provide business updates. To participate in the conference call...
Back to Newsroom